0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Neprilysin

Neprilysin

Neprilysin Molecule Information

Name:Neprilysin
Target Synonym:Common acute lymphocytic leukemia antigen?Neutral endopeptidase 24.11?NEP?Atriopeptidase?Neprilysin?CALLA?EPN?Neutral endopeptidase?MME?Skin fibroblast elastase?Enkephalinase?SFE?CD_antigen=CD10
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:32
Lastest Research Phase:Approved

Neprilysin Protein Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
MME-H521b Human Human Neprilysin / MME / CD10 Protein, Tag Free
MME-H521b-structure
MME-H521b-sds
MME-H526a Human Human Neprilysin / MME / CD10 Protein, Fc Tag
MME-H526a-structure
MME-H526a-sds

Neprilysin Molecule Synonym Name

MME,CALLA,CD10,DKFZp686O16152,MGC126681,MGC126707,NEP,SFE,Neprilysin

Neprilysin Molecule Background

Cluster of differentiation 10 (CD10) is also known as membrane metallo-endopeptidase, neutral endopeptidase (NEP), Neprilysin, and common acute lymphoblastic leukemia antigen (CALLA), is a 90-110-kDa type II transmembrane glycoprotein normally expressed by a variety of tissues, including epithelial cells of the prostate, kidney, intestine, endometrium, adrenal glands, and lung. This zinc-dependent metalloprotease enzyme cleaves peptide bonds on the amino side of hydrophobic residues and inactivates a variety of physiologically active secreted peptides. CD20 is thought to be the rate-limiting degrading enzyme of amyloid ¦Â peptide (A¦Â) whose abnormal misfolding and aggregation in neural tissue has been implicated in the development of Alzheimer's disease (AD). CD10 is also identified as the common acute lymphoblastic leukemia antigen (CALLA) present on leukemic cells of pre-B phenotype, and thus serves as the most important biomarker in the diagnosis of human acute lymphocytic leukemia (ALL).

Neprilysin References

Neprilysin Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Racecadotril Hidrasec; Tiorfan  Approved Bioprojet Racecadotril 法国 Diarrhea Bioprojet 1993-03-23 00:00:00.0 Diarrhea Details
Sacubitril/Valsartan LCZ-696,LCZ696 Approved Novartis ENTRESTO fda Heart failure NOVARTIS PHARMS CORP 2015-07-07 Cardiovascular disorders, Heart failure Details

Neprilysin Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Sacubitril/Allisartan Isoproxil S-086; AHU-377/EXP3174 Phase Ⅰ Salubris Chronic heart failure Details
Daglutril SLV-306; KC-12615,SLV306 Phase Ⅱ Abbvie Pulmonary arterial hypertension, Hypertension, Heart failure Details
Z-13752A Z-13752A; GW-660511X Phase Ⅱ Zambon, GlaxoSmithKline Hypertension Details
Gemopatrilat BMS-189921,BMS189921 Phase Ⅱ Bristol-Myers Squibb Hypertension, Heart failure Details
Ecadotril BAY-Y-7432; S-049; BP-1.02 Phase Ⅲ Bioprojet, Bayer, Shionogi Hypertension, Chronic heart failure Details
RB-105 RB-105; S-21402; S-21402-1 Phase Ⅰ Sanofi, INSERM Hypertension Details
PL-265 PL-265 Phase Ⅰ Pharmaleads Neuropathic pain Details
Omapatrilat BMS-186716; BMS-186716-01,BMS186716 Phase Ⅲ Bristol-Myers Squibb Hypertension, Heart failure, Angina pectoris Details
Sch-42495 Sch-42495 Phase Ⅱ Merck Sharp & Dohme Hypertension, Heart failure Details
TD-1439 TD-1439 Phase Ⅰ Theravance Biopharma Cardiovascular disorders, Kidney disorders Details
Candoxatrilat UK-73967 Phase Ⅱ Pfizer Renal failure, Heart failure Details
Sacubitril AHU-377,AHU377 Phase Ⅱ Novartis Heart failure Details
Ilepatril AVE-7688; MDL-107688 Phase Ⅱ Sanofi Hypertension, Diabetic nephropathy Details
MDL-100240 MDL-100240; 100240; M-100240 Phase Ⅱ Sanofi Hypertension, Heart failure Details
GW-796406 796406; GW-796406 Phase Ⅰ Zambon, GlaxoSmithKline Hypertension Details
Dexecadotril Phase Ⅲ Bioprojet Gastrointestinal disorders Details
UK-447841 UK-447841,UK447841 Phase Ⅱ Pfizer Female sexual dysfunction Details
SLV-334 SLV-334 Phase Ⅱ Abbvie Brain injury Details
CGS-25462 CGS-25462 Phase Ⅱ Novartis Hypertension, Heart failure Details
ONO-9902 ONO-9902 Phase Ⅱ Ono Pharmaceutical Cancer related pain Details
Sampatrilat UK-81252,UK81252 Phase Ⅱ Pfizer, Shire Hypertension, Heart failure Details
Candoxatril UK-79300 Phase Ⅲ Pfizer Hypertension, Heart failure Details
Sch-34826 Sch-34826 Phase Ⅱ Merck Sharp & Dohme Hypertension, Heart failure Details
AVE-804 AVE-8048; M-108048; MDL-108048 Phase Ⅰ Sanofi Hypertension Details
PF-505749 PF-505749; UK-502144; UK-505749,PF 505749; UK 502144; UK 505749,PF505749; UK502144; UK505749 Phase Ⅰ Pfizer Female sexual dysfunction Details
TD-0714 TD-0714; TD0714,TD0714 Phase Ⅰ Theravance Biopharma Hypertension, Heart failure, Chronic kidney disease Details
SLV-338 SLV-338 Phase Ⅰ Abbott Cardiovascular disorders Details
STR-324 STR-324 Phase Ⅰ Institut Pasteur, Stragen Pharma Pain Details
Debio-0827 Debio-0827; PL-37,Debio0827,PL37 Phase Ⅱ Pharmaleads, Debiopharm Group Pain Details
Fasidotril BP-1.137; BP-1137,BP1137 Phase Ⅲ Bioprojet, Lilly Hypertension, Heart failure, Myocardial infarction (MI) Details
LHW-090 LHW-090; LHV-527,LHV527,LHW090 Phase Ⅱ Novartis Hypertension Details
VNP-489 VNP-489 Phase Ⅰ Novartis Hypertension Details

This web search service is supported by Google Inc.

totop